These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer. Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812 [TBL] [Abstract][Full Text] [Related]
3. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project. Lee Y; Lee S; Sung JS; Chung HJ; Lim AR; Kim JW; Choi YJ; Park KH; Kim YH Cancer Res Treat; 2021 Jan; 53(1):123-130. PubMed ID: 32810930 [TBL] [Abstract][Full Text] [Related]
4. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081 [TBL] [Abstract][Full Text] [Related]
5. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients. Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758 [TBL] [Abstract][Full Text] [Related]
7. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409 [TBL] [Abstract][Full Text] [Related]
8. Association between somatic RET mutations and clinical and genetic characteristics in patients with metastatic colorectal cancer. Yang YZ; Hu WM; Xia LP; He WZ Cancer Med; 2021 Dec; 10(24):8876-8882. PubMed ID: 34741450 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686 [TBL] [Abstract][Full Text] [Related]
10. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406 [TBL] [Abstract][Full Text] [Related]
11. Systemic treatment for metastatic colorectal cancer. Leowattana W; Leowattana P; Leowattana T World J Gastroenterol; 2023 Mar; 29(10):1569-1588. PubMed ID: 36970592 [TBL] [Abstract][Full Text] [Related]
12. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers. Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272 [TBL] [Abstract][Full Text] [Related]
13. Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study. Udar N; Lofton-Day C; Dong J; Vavrek D; Jung AS; Meier K; Iyer A; Slaughter R; Gutekunst K; Bach BA; Peeters M; Douillard JY J Cancer Res Clin Oncol; 2018 Oct; 144(10):2001-2010. PubMed ID: 30019318 [TBL] [Abstract][Full Text] [Related]
14. Specific Mutations in APC, with Prognostic Implications in Metastatic Colorectal Cancer. Peng H; Ying J; Zang J; Lu H; Zhao X; Yang P; Wang X; Li J; Gong Z; Zhang D; Wang Z Cancer Res Treat; 2023 Oct; 55(4):1270-1280. PubMed ID: 37114476 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database. Nakamura Y; Olsen S; Zhang N; Liao J; Yoshino T Curr Oncol; 2022 May; 29(5):3433-3448. PubMed ID: 35621667 [TBL] [Abstract][Full Text] [Related]
17. Concordance Study of a 520-Gene Next-Generation Sequencing-Based Genomic Profiling Assay of Tissue and Plasma Samples. Wang M; Chen X; Dai Y; Wu D; Liu F; Yang Z; Song B; Xie L; Yang L; Zhao W; Zhang C; Shen W; Fan C; Teng C; Zhao X; Gao N; Shang D; Zhao G; Xin T Mol Diagn Ther; 2022 May; 26(3):309-322. PubMed ID: 35305253 [TBL] [Abstract][Full Text] [Related]
18. Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing. Harlé A; Filhine-Tresarrieu P; Husson M; Boidot R; Rouyer M; Dubois C; Leroux A; Merlin JL Target Oncol; 2016 Jun; 11(3):363-70. PubMed ID: 26661077 [TBL] [Abstract][Full Text] [Related]